In breast cancers, it is known that anti-HER2 approaches (such as antibodies or inhibitors) can be effective against HER2-overexpressing (and generally HER2-amplified) tumors, but not against cells with normal levels of HER2 [23]. The gene discussed is ERBB2; the disease is breast carcinoma.